The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Trevi Therapeutics Inc (NASDAQ: TRVI) closed at $6.49 in the last session, down -0.15% from day before closing price of $6.50. In other words, the price has decreased by -$0.15 from its previous closing price. On the day, 0.77 million shares were traded.
Ratios:
We take a closer look at TRVI’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.38 and its Current Ratio is at 15.38. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Raymond James on March 10, 2025, Upgraded its rating to Strong Buy and sets its target price to $29 from $9 previously.
On March 10, 2025, Needham reiterated its Buy rating and also lowered its target price recommendation from $8 to $25.
H.C. Wainwright reiterated its Buy rating for the stock on December 12, 2024, while the target price for the stock was revised from $6 to $7.50.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 25 ’25 when SCIASCIA THOMAS sold 2,631 shares for $6.60 per share. The transaction valued at 17,365 led to the insider holds 221,373 shares of the business.
GOOD JENNIFER L sold 5,263 shares of TRVI for $34,625 on Mar 21 ’25. The President & CEO now owns 213,313 shares after completing the transaction at $6.58 per share. On Mar 21 ’25, another insider, GOOD JENNIFER L, who serves as the Officer of the company, bought 5,263 shares for $6.58 each.
Stock Price History:
Over the past 52 weeks, TRVI has reached a high of $7.39, while it has fallen to a 52-week low of $2.30. The 50-Day Moving Average of the stock is 2.55%, while the 200-Day Moving Average is calculated to be 56.18%.
Shares Statistics:
A total of 99.89M shares are outstanding, with a floating share count of 59.67M. Insiders hold about 41.36% of the company’s shares, while institutions hold 51.49% stake in the company.
Earnings Estimates
Currently, 6.0 analysts are dedicated to thoroughly evaluating and rating the performance of Trevi Therapeutics Inc (TRVI) in the stock market.The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.09 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.38 and -$0.51 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.51, with 6.0 analysts recommending between -$0.26 and -$0.66.
